US3545927A - Measurement of cell membrane kinetics - Google Patents

Measurement of cell membrane kinetics Download PDF

Info

Publication number
US3545927A
US3545927A US653420A US3545927DA US3545927A US 3545927 A US3545927 A US 3545927A US 653420 A US653420 A US 653420A US 3545927D A US3545927D A US 3545927DA US 3545927 A US3545927 A US 3545927A
Authority
US
United States
Prior art keywords
cells
uptake
cation
rate
radioactive
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
US653420A
Other languages
English (en)
Inventor
Kenneth G Scott
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
KENNETH G SCOTT
Original Assignee
KENNETH G SCOTT
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by KENNETH G SCOTT filed Critical KENNETH G SCOTT
Application granted granted Critical
Publication of US3545927A publication Critical patent/US3545927A/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N15/00—Investigating characteristics of particles; Investigating permeability, pore-volume or surface-area of porous materials
    • G01N15/08—Investigating permeability, pore-volume, or surface area of porous materials
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10S435/00—Chemistry: molecular biology and microbiology
    • Y10S435/81—Packaged device or kit

Definitions

  • the method includes the establishment of the equilibrium point where passive diffusive movement of ions into and out of the cells is substantially equal, at which time the pumping or active transport rate of the cells can be determined.
  • the passive rate in terms of outward diffusion is then determined based upon the previously determined active rate.
  • Apparatus employing ion exchange resins for making the measurements needed for determining the active and passive rates is also provided.
  • This invention relates to the measurement of cell membrane kinetics. More particularly, the invention provides a method and apparatus for measuring both active and passive rates of cation transport by cells by monitoring the passage of radioactive cations across the cell membrane. Changes from the norm are used as an indication of the presence of cancer in the patient.
  • the present invention is designed to accumulate data on the permeability of cells, particularly red blood cells, that is generally reproducible and interpretable in terms of identifying patients who have cancer. All prior work in this area has simply established that a decrease from normal of the net accumulation of a radioactive cation by the red blood cells of cancer patients exists.
  • the present invention provides a method for determining both the active and passive accumulation rates by cells and relates these rates in cells from a cancer patient to a norm. It has been discovered that these two rates can both be effectively usde for comparison against standards in screening for the presence of cancer and its management. Although cancer will be used to illustrate the principles involved, the methods are equally applicable to investigation of such disorders as heart disease, anemia, and schizophrenia.
  • the present invention is based on the finding that cells such as red blood cells exhibit a rate of change of cation uptake which consists of two components-an early fast component and a subsequent slower one.
  • the fast component involves both the passive diffusion of cations into the cell and the active uptake by the cell. Initially, both the active uptake and passive diffusion are working in the same direction. At a later point, these components diverge as the cation concentration in the cell exceeds that of the surrounding diluent. The point where the rate change occurs represents that point where the passive diffusion is in a state of substantial equilibrium into and out of the cell. Rate measurements made at this time represent the active transport United States Patent 3,545,927 Patented Dec. 8, 1970 rate or pumping rate of the cell. Location of the equilibrium point (referred to as point B herein) is crucial to the invention. Only after it is located can the passive and active transport rates be determined. Two methods for locating point E will be discussed herein.
  • passive diffusion can be determined based upon this pumping rate.
  • measurements are made at a time subsequent to the equilibrium point and the difference between the observed cation content of the cell and that which would theoretically be present based upon the pumping rate (assumed to be constant) in the absence of outward dilfusion provides data indicative of the outward diffusion of the cells.
  • Both the active uptake rates and the outward diffusion rates of cancer cells are shown in the present invention to be consistently significantly higher than those of control non-cancer patients and of normal subjects. In other investigations, the rates of patients being tested may vary from the norm in the opposite direction. For example, in studies on schizophrenics, the rates were found to be significantly lower than the norm.
  • FIG. 1 shows in schematic side section apparatus suitable for measuring cell kinetics in accordance with the present invention
  • FIG. 2 shows in side elevation the device of FIG. 1 in a rotated position required for use
  • FIG. 3 shows in side section an alternative embodiment of a device for practicing the present method
  • FIG. 4 shows in side elevation the device of FIG. 3 in an inverted position as required for use
  • FIGS. 5-7 are plots of data taken from measurements on red blood cells of non-cancer hospitalized patients, cancer patients, and normal subjects, respectively, in accordance with the present method and illustrating the increased active uptake and outward diffusion rates of the cancer patients as compared with the other two groups.
  • the present methods are applicable to the study of all types of cells.
  • the ready availability of red cells and the comprehensive studies of their kinetics that have already been done make them preferably for illustrative purposes.
  • the experimental work to be discussed has therefore been obtained on erythrocytes.
  • any suitable radioactive tracer element is conveniently selected. Because of its convenient decay scheme (18.6 day half-life), high specific activity (1.0 mev. gamma emission) of readily available radioactive rubidium, and the similarity between Rb and potassium transport by red blood cells, Rb is the preferred tracer for the study of erythrocyte kinetics. These properties permit use of the Rb isotope without overloading the potassium pool of the cells which would in turn alter cation kinetics.
  • Table I and plotted in the curves of FIGS. 57 of the accompanying drawings illustrates the type of results to be expected with the present methods and concepts. The data was obtained in the following manner:
  • the red blood cell Rb kinetics of three groups of adult human males were studied.
  • the groups consisted of (1) patients with cancer, (2) controls, hospitalized for conditions other than cancer, and (3) normal subjects who were members of the academic staff of the University of California Medical Center at San Francisco, Calif., and in good health.
  • Diagnosis of the cancer patients were based upon histological examination of the suspect tissue.
  • the controls used for statistical comparison were patients hospitalized for the following disorders: cardiovascular 10, gastrointestinal 6, endocrine 3, trauma 5, neuroskeletal 5, arthritis 7, infection 4.
  • the age of the cancer subjects averaged 592:.8 years with a range of 23-90 years.
  • Those used as hospital controls had an average age of 49.4:3 years with a range of 25-75 years.
  • the average age of the normals was 45.1:2 years and ranged from 30 to 60 years.
  • the counting rate of the )lasma at the 4 minute point is taken as 100 percent. This s done for several reasons. Data obtained from whole lood or extrapolation of the red blood cell uptake curve :hows that on an average about 5% of the Rb is in- :orporated in the cells in the first four minutes. A rapid lptake component described by Kahn 1 is also present in he first four minute uptake. This uptake is usually less ban 5% and may be demonstrated by treating the incuiated cells with 20 volumes of isotonic rubidium chloride tnd comparing this release with cells from the same ample treated with isotonic saline. This release occurs rut once following treatment with rubidium and this rapily exchangeable component is not considered as part of he Rb involved in cell transport.
  • the red blood cell cation uptake following the first 4 minutes is conveniently determined from the reciprocal ass of radioactive cations from the plasma.
  • the uptake f the red blood cells of each patient was plotted on linear aper.
  • the individual uptakes for each point are comined to provide data for curves of the several groups as hown in FIGS. 5, 6, and 7.
  • passive diffusion equilibri- F m point E only active uptake is considered to be a sigificant factor in the accumulation of Rb by the cells.
  • the pumping rate (AU) of the cells for Rb can be established from a tangent to the uptake curve at point B. If glucose is added to maintain cell metabolism, this rate can be taken as constant during the selected time of cell incubation (140 minutes in this example).
  • the location of point E on a cation uptake curve is obtained by either of two methods. These are: (1) measuring distribution of "Rb between cells and plasma in blood stored at 0.2 to 08 to obtain the cation space of the cell with respect to the plasma, and (2) determination of the point on the uptake curve where the change in rate is minimal.
  • Method 1 Active pumping by Rb has been shown to be inhibited at temperatures below 4 C. Twelve specimens were taken from cold stored blood at 24, 48, and 72 hours and similar results were obtained. Rb space of red blood cells was found to average .402:.03 of that of plasma. For the preferred trace, point B is accordingly determined from cation space as follows:
  • Tan T was obtained from the Rb uptake curve of each subject plotted on linear paper using the straight line method or by determining Point E using the ion space method as described. Tan T is expressed as the time in minutes that of the initial plasma Rb would be actively transported by the cells. The time for Tan E so obtained was corrected for any difference in packed cell volume using the control of 42.
  • the average outward diffusion (OD) could then be determined by subtracting the amount actually present in the cells (OBS) from the amount which would have entered by active pumping in a given interval (AUXtime in minutes) corrected for any difference in packed cell volume. In this case a four minute interval was elected.
  • the active uptake rate can be determined in accordance with the following formula:
  • Table I and FIGS. 5-7 demonstrate the significantly different results obtained in the cancer group compared with the other two groups. These differences are sufficient to indicate the presence of cancer.
  • suitable therapy including X-ray and chemotherapy
  • the red blood cell kinetics gave varying results when compared to untreated cancer patients of the same type or as compared with controls.
  • Most patients receiving chemotherapy showed a reduction in the normally high Rb red cell uptake observed in untreated cancer patients.
  • Following chemotherapy only outward diffusion was observed to be significantly different than normal.
  • the method can thus be used to detect an early cancer, measure the activity of a known cancer, or reflect the suppressive effect of various therapies on this activity.
  • the approximations are used for determining the active uptake and outward diffusion as before.
  • the amount present in the cells at 40 minutes represents the amount of uptake at the approximated equilibrium point.
  • the second reading is taken at an arbitrary time sufficiently long to provide significant data so that an average rate can be computed between the two points.
  • the arbitrary time selected should be short of that time where an overall plasma cell equilibrium is reached.
  • the formula for outward diffusion (which represents net loss by outward diffusion) is simply divided by the number of minutes between point E and the final time such as 140 minutes or other selected time when the net uptake is determined. Since point E is not determined in this approximate approach, it must be estimated.
  • point B will generally fall at about 40 minutes so that the estimated time period during which the outward diffusion is occurring will be about minutes (-40). Whereas a figure of 100 minutes is a good average, a variation from 80-120 minutes will provide usable information depending on other conditions involved.
  • FIGS. 1-4 suitable apparatus for making the measurements required to practice the invention is illustrated.
  • the devices offer the advantages of simplicity and ready adaptation to clinical testing in a kit form.
  • a device comprising a pair of parallel chambers 10 and 11 are joined at one end with a transverse conduit 12.
  • Chamber 11 includes an inlet 13 with a mating stopper 14 that is operable for introducing a blood sample into chamber 11.
  • Chamber 11 further includes a radioactive cation source 15.
  • suitable additives such as glucose may be included to support cell respiration.
  • Radioactive source 15 is preferably an Rb source of about 5 microcuries, for example. Incubation is suitably conducted at about 37 C. for selected intervals.
  • chamber 11 is rotated about rotatable joint 27 so that instead of the U configuration of FIG. 1, the configuration illustrated in FIG. 2 is obtained. Pursuant to the rotation, the incubated blood sample in chamber 11 is discharged into chamber 10 through conduit 12.
  • Chamber 10 includes a cation exchange resin 16 retained at the bottom by porous plate 16a. Any strong cation exchange resin with an affinity for the selected radioactive cation such as Rb is suitably used.
  • a typical material is Ag50, a cation exchange resin made by Dow Chemical Company. With respect to the quantities of fluid discussed above, it is suitable to use about 125 mg. of 50-100 mesh resin in chamber 10.
  • the resin takes up only rubidium present in the plasma, but not from the red cells. Because of this there is no need to first separate the cells and plasma.
  • the amount of radioactive cation taken up by the cells can be established from the difference between the two values.
  • chamber can be handled as a tube and the tracer counted, for example, in a suitable automatic scintilaltion spectrometer in the usual way.
  • excess blood solution will usually be washed from the resin with a suitable isotonic solution designed to wash the resin without removing the radioactive cation in the resin.
  • chamber 10 and 11 and transverse conduit 12 can be made from a flexible material such as polyethylene so that it can be bent into a relatively straight line to promote drainage from chamber 11 to chamber 10. This would eliminate the need for rotatable joint 27. In either case chamber 10 can be inserted into a radioactive counter while attached to the device or if desired chamber 10 may be severed before counting.
  • FIGS. 3 and 4 illustrate an alternative embodiment for practicing the present method.
  • a container 17 is used to hold a blood sample 17a, together with desired glucose or other additives.
  • An elongate stick 18 includes a first end 19 that is recessed at 20.
  • a radioactive cation source 21 is mounted within recess 20.
  • Cover 22 is apertured or otherwise made permeable to allow contact and dissolving of the cation source 21 into the blood sample 17a when end 19 is inserted therein, as shown in FIG. 4.
  • the opposite end 23 of stick 18 is similar to end 19 and includes a recess 24 and fluid permeable cover 25. Instead of a radioactive source, recess 24 contains a cation exchange resin 26.
  • the amount of blood sample and the blood cell count are first determined.
  • the measurements can then be made in one of two ways. If the initial amount of radioactive cation dissolved into the diluent or plasma is known, the cell uptake is simply calculated by measuring the amount in the resin. Uptake by the cells represents the difference between the initial amount of cation and that present in the resin.
  • the resin can be preloaded with a known amount of radioactive cation. Following a period of contact between the blood sample and the resin, the amount of radioactive cation remaining in the resin can be counted. The difference between the starting preloaded concentration in the resin and that remaining following incubation represents the amount taken up by the blood cells.
  • a first reading can be made at 40 minutes of incubation and a second reading at 140 minutes of incubation.
  • a method for measuring cell membrane kinetics comprising: providing cells to be measured in a physiological diluent; adding radioactive cations to said solu tion for uptake by said cells; determining the equilibrium point where passive diffusive movement of ions into and out of said cells is substantially equal; and measuring the rate of uptake of said radioactive cations by said cells at said equilibrium point, the rate of said equilibrium point being the pumping or active transport rate for the cells, said rate of uptake being measured indidirectly by determining the rate of radioactive cation disappearance from the physiological diluent by measuring the amount of radioactive cations in the physiological diluent in the presence of said cells by contacting the diluent and cells with a cation exchange resin and measuring the amount of radioactive cation in said resin following said contact.
  • said cells are red blood cells
  • said physiological diluent is blood plasma
  • the said equilibrium point is determined from the formula P-
  • the improvement comprising determining the equilibrium point Where passive diffusive movement of the ions into and out of said cells is substantially equal; measuring the active rate of the uptake of cations by the cells at said equilibrium point; and then determining the passive rate of cation transport of said cells based upon the previously determined active uptake rate, said rate of uptake being determined by contacting the cells with a cation exchange resin and meas- 9. uring the amount of radioactive cation in said resin following said contact.

Landscapes

  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pathology (AREA)
  • Immunology (AREA)
  • General Physics & Mathematics (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Physics & Mathematics (AREA)
  • Hematology (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Dispersion Chemistry (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
US653420A 1967-07-14 1967-07-14 Measurement of cell membrane kinetics Expired - Lifetime US3545927A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US65342067A 1967-07-14 1967-07-14

Publications (1)

Publication Number Publication Date
US3545927A true US3545927A (en) 1970-12-08

Family

ID=24620817

Family Applications (1)

Application Number Title Priority Date Filing Date
US653420A Expired - Lifetime US3545927A (en) 1967-07-14 1967-07-14 Measurement of cell membrane kinetics

Country Status (7)

Country Link
US (1) US3545927A (sh)
BE (1) BE717972A (sh)
DE (1) DE1773809A1 (sh)
FR (1) FR1574417A (sh)
GB (1) GB1239447A (sh)
NL (1) NL6809909A (sh)
SE (1) SE345743B (sh)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3143778A1 (de) * 1980-11-07 1982-06-16 Harnischfeger Corp., 53246 West Milwaukee, Wis. Kran mit stabilisations-ausfahrstuetzen und vertikal positionierbaren aufbockwinden
US4343782A (en) * 1978-04-20 1982-08-10 Shapiro Howard M Cytological assay procedure
EP3953000A4 (en) * 2019-04-11 2023-06-07 Ian Basil Shine CELL MEMBRANE PERMEABILITY RESTORATION THERAPY

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE1110303B (de) * 1959-10-20 1961-07-06 Egon Westermann Leuchte mit an einem Leuchtenkoerper befestigten Leuchtenarmen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
None *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4343782A (en) * 1978-04-20 1982-08-10 Shapiro Howard M Cytological assay procedure
DE3143778A1 (de) * 1980-11-07 1982-06-16 Harnischfeger Corp., 53246 West Milwaukee, Wis. Kran mit stabilisations-ausfahrstuetzen und vertikal positionierbaren aufbockwinden
EP3953000A4 (en) * 2019-04-11 2023-06-07 Ian Basil Shine CELL MEMBRANE PERMEABILITY RESTORATION THERAPY

Also Published As

Publication number Publication date
NL6809909A (sh) 1969-01-16
GB1239447A (sh) 1971-07-14
FR1574417A (sh) 1969-07-11
SE345743B (sh) 1972-06-05
BE717972A (sh) 1969-01-13
DE1773809A1 (de) 1971-10-28

Similar Documents

Publication Publication Date Title
Weinberg et al. Biologically active products of complement and acute lung injury in patients with the sepsis syndrome
EP0350162B1 (en) Automated multi-point blood volume analyzer
EP0487606B1 (en) Methods and apparatus for quantifying tissue damage
Garrett et al. Zinc protoporphyrin and iron deficient erythropoiesis
US3545927A (en) Measurement of cell membrane kinetics
Blaufox et al. Measurement of renal function in the rat with single injection clearances
Bishop et al. Comparison of a manual and an automated enzymatic technique for determining blood lactate concentrations
RAGEN et al. Radioisotopic study of anemia in chronic renal disease
Perales Blood volume analysis by radioisotopic dilution techniques: state of the art
Myant et al. The thyroid clearance rate of plasma iodine as a measure of thyroid activity
ALBERT et al. Pittalls in Blood Volume Measurement
Toffaletti et al. Increase in dialyzable calcium associated with therapy with lithium.
Danielson et al. Effect of citrate concentration in specimen collection tubes on the international normalized ratio
Oliva-Damaso et al. Fluctuation of pre-hemodialysis serum sodium
Biswas et al. Heparin effect on ionised calcium concentration
Chothia et al. A method comparison study of a point-of-care blood gas analyser with a laboratory auto-analyser for the determination of potassium concentrations during hyperkalaemia in patients with kidney disease
Garby et al. Short-term assessment of red cell survival with an improved Cr51-technique
Weinberg et al. Measurement of relative coronary blood flow by precordial monitoring
RU2191383C2 (ru) Способ определения послеоперационной кровопотери
Azam et al. Hyponatremia Prevalence in Decompensated Chronic Liver Disease: Insights from a Tertiary Care Hospital
Mantzos et al. Isotopic determination of serum vitamin B12 level using Sephadex G-25
Schifman et al. Predonation hematocrit measurement by whole blood electrical conductivity assay
Ruggles XXXII Blood Loss during Adenoidectomy and Tonsillectomy Measured with Radioisotopes
McNulty et al. Bedside hemoglobin measurements: sensitivity to changes in serum protein and electrolytes
Brozovic et al. Simultaneous red cell and plasma volume determinations by a differential absorption method